PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
1.50
0.5–0.75x AGEN's 2.01. Martin Whitman would question if short-term obligations are sufficiently covered.
1.50
0.5–0.75x AGEN's 2.01. Martin Whitman might be concerned about coverage if a crisis hits.
1.48
0.75–0.9x AGEN's 1.87. Bill Ackman might want more safety or minimal liabilities.
-2327.49
Both companies show negative interest coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
-27.48
Both companies show negative short-term coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.